more

Intellia Therapeutics (NTLA)

(Real Time Quote from BATS)

$26.53 USD

+0.11 (0.42%)

Updated Jul 26, 2024 03:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.15%
2	Buy	17.88%
3	Hold	9.47%
4	Sell	5.14%
5	Strong Sell	2.57%
S&P	500	11.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag

by Zacks Equity Research Published on January 07,2019

FDA grants a Fast Track designation to Vertex (VRTX) and CRISPR Therapeutics' gene editing candidate, CTX001, for the treatment of sickle cell disease.

biotechs

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on October 31,2018

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -10.42% and -36.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

NTLAPositive Net Change

Intellia Therapeutics, Inc. (NTLA) Q3 Earnings Preview: What's Shaping Up?

by Zacks Equity Research Published on October 23,2018

Intellia Therapeutics, Inc. (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NTLAPositive Net Change

Guide to CRISPR Stocks & Latest Apple, Fed, GDP News | Free Lunch

by Ryan McQueeney Published on September 27,2018

Ryan McQueeney highlights the Fed's latest rate hike sentiment and new revisions to GDP growth estimates. He also recaps Bed Bath & Beyond's earnings results and touches on analyst research related to Apple. Later, he is joined by Zacks' biotech guru, Kevin Cook, to chat about CRISPR stocks and how to invest in the developing science.

Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

by Sweta Killa Published on September 12,2018

Sector ETF report for ARKG

Should You Invest in the ARK Innovation ETF (ARKK)?

by Sweta Killa Published on September 10,2018

Sector ETF report for ARKK

Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?

by Zacks Equity Research Published on August 20,2018

Sector ETF report for ARKG

Should You Invest in the ARK Innovation ETF (ARKK)?

by Zacks Equity Research Published on August 16,2018

Sector ETF report for ARKK

Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on August 01,2018

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of 8.77% and 20.20%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?